ALK and breast cancer: Table 2 summarizes the clinical characteristics of individual patients. Median age was 66 years (interquartile range, IQR: 51–72) and the majority of subjects were male (n = 15, 65%) and had lung cancer (n = 18, 78%). No BC patient was enrolled. Bio-molecular characterization was not available in 5 cases. Among lung cancer patients, EGFR mutations were detected in 4 cases, ALK translocation in 1 case and KRAS mutation in another case. Two of the three CRC patients harboured a KRAS mutation.